Page 166 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Chapter 5
Ther. 2018;103(4):599-618.
17. Henricks LM, Kienhuis E, de Man FM, et al. Treatment algorithm for homozygous or compound
heterozygous DPYD variant allele carriers with low dose capecitabine. JCO Precis Oncol. 2017.
18. NCI. National Cancer Institute: Common Terminology Criteria for Adverse Events v4.03. https:// evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf, 5 May 2017.
19. SKML. Dutch Foundation for Quality Assurance of Medical Laboratory Diagnostics. [Website].
2017; https://skml.nl/. Accessed 05 May 2017.
20. Deenen MJ, Meulendijks D, Boot H, et al. Phase 1a/1b and pharmacogenetic study of
docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the
gastroesophageal junction. Cancer Chemother Pharmacol. 2015;76(6):1285-1295.
21. Van Kuilenburg ABP, Van Lenthe H, Tromp A, Veltman PC, Van Gennip AH. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem. 2000;46(1):9-
17.
22. A’Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med. 2001;20(6):859-
866.
23. Van Kuilenburg ABP, Meinsma R, Zoetekouw L, Van Gennip AH. Increased risk of grade IV
neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase
deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer. 2002;101(3):253-258.
24. Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of
enzyme activity. Cancer Res. 2013;73(6):1958-1968.
25. Lunenburg CATC, Henricks LM, Guchelaar HJ, et al. Prospective DPYD genotyping to reduce the
risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. Eur J Cancer. 2016;54:40-
48.
26. Boisdron-Celle M, Capitain O, Faroux R, et al. Prevention of 5-fluorouracil-induced early severe
toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment
of a multiparametric approach. Semin Oncol. 2017;44(1):13-23.
27. Elraiyah T, Jerde CR, Shrestha S, et al. Novel Deleterious Dihydropyrimidine Dehydrogenase
Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population. Clin Pharmacol Ther. 2017;101(3):382-390.
164